Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years

ABSTRACTThe human papillomavirus type 16/18 (HPV-16/18) AS04-adjuvanted cervical cancer vaccine is licensed for females aged 10 years and above and is therefore likely to be coadministered with other licensed vaccines, such as hepatitis B. In this randomized, open-label study, we compared the immunogenicity of the hepatitis B vaccine administered alone (HepB group) or with the HPV-16/18 AS04-adjuvanted vaccine (HepB+HPV group) in healthy women aged 20 to 25 years (clinical trial NCT00637195). The hepatitis B vaccine was given at 0, 1, 2, and 12 months (an accelerated schedule which may be required by women at high risk), and the HPV-16/18 vaccine was given at 0, 1, and 6 months. One month after the third dose of hepatitis B vaccine, in the according-to-protocol cohort (n= 72 HepB+HPV;n= 76 HepB), hepatitis B seroprotection rates (titer of ≥10 mIU/ml) were 96.4% (95% confidence interval [CI], 87.5 to 99.6) and 96.9% (CI, 89.2 to 99.6) in the HepB+HPV and HepB groups, respectively, in women initially seronegative for anti-hepatitis B surface antigen (HBs) and anti-hepatitis B core antigen (HBc). Corresponding geometric mean titers of anti-HBs antibodies were 60.2 mIU/ml (CI, 40.0 to 90.5) and 71.3 mIU/ml (CI, 53.9 to 94.3). Anti-HBs antibody titers rose substantially after the fourth dose of hepatitis B vaccine. All women initially seronegative for anti-HPV-16 and anti-HPV-18 antibodies seroconverted after the second HPV-16/18 vaccine dose and remained seropositive up to 1 month after the third dose. Both vaccines were generally well tolerated, with no difference in reactogenicity between groups. In conclusion, coadministration of the HPV-16/18 AS04-adjuvanted vaccine did not affect the immunogenicity or safety of the hepatitis B vaccine administered in an accelerated schedule in young women.

Download Full-text

O833 HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Correlation between serum and mucosal anti-HPV-16 and anti-HPV-18 antibody levels

International Journal of Gynecology & Obstetrics ◽

10.1016/s0020-7292(09)61206-6 ◽

2009 ◽

Vol 107 ◽

pp. S331-S331 ◽

Cited By ~ 1

Author(s):

T. Schwarz ◽

M. Kocken ◽

T. Petäjä ◽

M. Einstein ◽

K. Hardt

Keyword(s):

Cervical Cancer ◽

Cancer Vaccine ◽

Hpv 16 ◽

Cervical Cancer Vaccine ◽

Antibody Levels ◽

Hpv 18

Download Full-text

Cervical cancer vaccine development

Sexual Health ◽

10.1071/sh09132 ◽

2010 ◽

Vol 7 (3) ◽

pp. 230 ◽

Cited By ~ 7

Author(s):

Ian H. Frazer

Keyword(s):

Cervical Cancer ◽

Clinical Trials ◽

Human Papillomavirus ◽

Cancer Vaccine ◽

Vaccine Development ◽

Global Burden ◽

Viral Capsids ◽

Cervical Epithelium ◽

Papillomavirus Vaccines ◽

Cervical Cancer Vaccine

Cervical cancer is initiated by infection of cervical epithelium with human papillomavirus. Vaccines have been developed, incorporating papillomavirus viral capsids and alum based adjuvants. In extensive clinical trials these vaccines have been shown safe and effective in preventing infection with, and disease caused by, the papillomavirus genotypes they incorporate, in women not already infected. These vaccines have the potential to reduce the global burden of cervical cancer by up to 70%.

Download Full-text

Immunoinformatics Study on Early 4 Protein of Human Papillomavirus Type 16 for Cervical Cancer Vaccine Peptide Candidate

Jurnal Biodjati ◽

10.15575/biodjati.v4i2.5414 ◽

2019 ◽

Vol 4 (2) ◽

pp. 252-262

Author(s):

Yani Suryani ◽

Opik Taupiqurrohman ◽

Muhammad Yusuf ◽

Toto Subroto ◽

Sukma Nuswantara

Keyword(s):

Cervical Cancer ◽

Human Papillomavirus ◽

Amino Acid ◽

Cancer Vaccine ◽

Vaccine Candidate ◽

Peptide Vaccine ◽

Human Papillomavirus Type 16 ◽

Cervical Cancer Vaccine ◽

Peptide Candidate

The aims of this study were to carry out testing of the early 4 protein of type 16 HPV through immunoinformatics meth-ods in an effort to get the peptide vaccine candidate for cervical cancer. The software used are IEDB-AR, CABSdock and Accelrys Discovery Study 4.5. Based on the analysis that sequence of ami-no acid lysine, leucine, leucine, glycine, serine, threonine, tryp-tophan, proline and threonine (KLLGSTWPT) and the sequence of amino acid tyrosine, tyrosine, valine, leucine, histidine, leucine, cysteine, leucine, alanine, alanine, threonine, lysine, tyrosine, pro-line and leucine (YYVLHLCLAATKYPL) are peptide vaccine can-didate for cervical cancer from the early 4 protein of HPV type 16

Download Full-text